Nanobiotix S.A. announced the appointment of Arnd Christ as Chief Financial Officer and member of the executive board, effective October 1, 2026. Mr. Christ succeeds Bart Van Rhijn, who served in the role for five years before stepping down. Nanobiotix is a late-stage clinical biotechnology company pioneering physics-based therapeutic approaches to treat cancer and other major diseases.
